BERLIN and SEATTLE, Oct. 27, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported the PRESEPT Clinical Study Steering Committee had reviewed the substantial progress that has been made in the execution of the PRESEPT Study. In addition, Dr. Timothy Church has been assigned responsibility for study results analysis and Prof. Dr. Thomas Rosch has been added to the Committee as representative of the German sites.